Lupin Diagnostics, a 100 percent subsidiary of Lupin Limited, has set up a state-of-the-art 45,000 sq. ft National Reference Laboratory in Navi Mumbai to offer services to doctors, patients and consumers
Mumbai-based pharma major Lupin Limited on December 10 announced the launch of its diagnostics business, with its subsidiary commencing operations in the country.
Lupin Diagnostics, a 100 percent subsidiary of Lupin Limited, has set up a state-of-the-art 45,000 sq ft National Reference Laboratory in Navi Mumbai, the company said in a regulatory filing.
“With healthcare playing an increasingly important role, Lupin Diagnostics’ goal is to provide quality diagnostics services to doctors, patients and consumers,” the company said.
With world-class equipment, experienced doctors assisted by trained technologists, and stringent quality control protocols, Lupin Diagnostics would provide a comprehensive range of diagnostic tests, it said.
The tests “would include molecular diagnostics, cytogenetics, flow cytometry, microbiology, serology, histopathology and cytology, haematology, immunology, amongst others”, it said.
The laboratory in Navi Mumbai will include all major diagnostics services, preventive health checkups, and a comprehensive range of tests, the statement noted.
All the processing will be operated by Lupin Healthcare as a hub and will be connected to a nation-wide network of regional, satellite and collection centres.
Lupin was identifying franchisee partners willing to serve the needs of patients with a singular motto of “Quality & Care”, it said.
Lupin Limited is an Indian multinational pharmaceutical company based in Mumbai, Maharashtra, India. It is one of the largest generic pharmaceutical companies by revenue globally. The company’s key focus areas include paediatrics, cardiovascular, anti-infectives, diabetology, asthma and anti-tuberculosis.
Lupin was founded in 1968 by Desh Bandhu Gupta , who was a professor of chemistry at BITS-Pilani, Rajasthan. Gupta moved to Mumbai in the 60s to work on his business enterprise for which initially he had initially borrowed Rs 5000 from his wife to fund his venture. Subsequent funding from Central Bank of India, the company was able to start their manufacturing facility for producing folic acid and iron tablets for Government of India mother and child health program. Later Lupin started manufacturing anti TB drugs which at one point formed 36% of the company sales and was considered as the largest TB drugs manufacturer in the world.
After success with Lupin, in 1988 Gupta founded the group’s CSR arm, the Lupin Human Welfare & Research Foundation (LHWRF). This initiative was dedicated to sustainable rural development with the aim to uplift families living below the poverty line.
As the company grew, in July 2015 the company announced its intention to acquire Gavis Pharmaceuticals and Novel Laboratories for $880 million.
In March 2019, the US FDA put several Lupin drug plants on notice for quality problems, and indicated it might not approve future Lupin drug applications.
For more Information: Sign in Websites for Agrochemical & Pharmaceutical Databases:
Website : https://www.chemrobotics.com/ (Agrochemical Databases)
Website : https://chemroboticspharma.com/ (Pharmaceutical Databases)